Treatment of MRSA pneumonia: Clinical and economic comparison of linezolid vs. vancomycin – a retrospective analysis of medical charts and re-imbursement data of real-life patient populations

2017/01/27 by Michael Wilke, Karsten Becker, Wilke, Michael H. +15
Medicine · #610 Medical sciences #Antibiotics Pharmacokinetics and Efficacy #Antimicrobial Resistance in Staphylococcus #Medicine #Pfizer #Pneumonia and Respiratory Infections #Zyvox® #cost-benefit analysis #linezolid #methicillin resistant Staphylococcus aureus #pneumonia #treatment outcome #vancomycin

paper · doi:10.3205/id000028

openalex publication_date 2017/01/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/19

Abstract

These findings confirm in a routine clinical setting that linezolid is a valuable therapeutic alternative to vancomycin for the treatment of MRSA pneumonia. However, prospective studies in real-life patient populations are warranted.

Related

• Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data
• Comparative effectiveness of ceftaroline plus vancomycin or daptomycin versus vancomycin or daptomycin monotherapy for MRSA bacteremia: an updated systematic review and meta-analysis
• Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
• Effects of Broad-Spectrum Antimicrobials on Patients with Community-Acquired Pneumonia with Low Risk for Drug-Resistant Pathogens: Historical Cohort Study in Japan
• Where antibiotic time-outs work: department- and ward-stratified effects of a pharmacist-led anti-MRSA time-out